Correction: Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer (Clinical Cancer Research (2012) 18 (758-770) DOI: 10.1158/1078-0432.CCR-11-1980);Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 758-770

  Sun, Jessica D ^a   Liu, Qian ^a   Wang, Jingli ^a   Ahluwalia, Dharmendra ^a   Ferraro, Damien ^a   Wang, Yan ^a   Duan, Jian Xin ^a   Ammons, W Steve ^a   Curd, John G ^a   Matteucci, Mark D ^a   Hart, Charles P ^a  

^a Threshold Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(1 METHYL 2 NITRO 1H IMIDAZOLE 5 YL) N, N' BIS(2 BROMOETHYL) DIAMIDOPHOSPHATE; 2 NITROIMIDAZOLE DERIVATIVE; HISTONE H2AX; PIMONIDAZOLE; TH 302; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL HYPOXIA; CELL ISOLATION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MORPHOMETRICS; MOUSE; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84863012236     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-24-1058     Document Type: Erratum

References (48)

1. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47. (Pubitemid 37328806)
2. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393-410.
3. Sun X, Niu G, Chan N, Shen B, Chen X. Tumor hypoxia imaging. Mol Imaging Biol 2010;13:399-410.
4. Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC. Immunohistochemical detection of changes in tumor hypoxia. Int J Radiation Oncology Biol Phys 2009;73:1177-86.
5. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008;14:1340-8. (Pubitemid 351413913)
6. Le QT, Courter D. Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev 2008;27:351-62.
7. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39. (Pubitemid 47101660)
8. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9. (Pubitemid 26396294)
9. 2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002;60:634-9.
10. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2a and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24:727-35. (Pubitemid 46622039)
11. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91. (Pubitemid 26008141)
12. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3. (Pubitemid 26065381)
13. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003;20:237-50. (Pubitemid 36513228)
14. Duncan W. Exploitation of the oxygen enhancement ratio in clinical practice. Brit Med Bull 1973;29:33-8.
15. Suit HD: Modification of radiation response. Int J Radiat Oncol Biol Phys 1984;10:101-8.
16. Williams KJ, Cowen RL, Brown LM, Chinje EC, Jaffar M, Stratford IJ. Hypoxia in tumors: molecular targets for anti-cancer therapeutics. Adv Enzyme Regul 2004;44:93-108. (Pubitemid 39568167)
17. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 2002;9:291-6. (Pubitemid 34256904)
18. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47. (Pubitemid 38745529)
19. Denny WA, Wilson WR. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev 1993;12:135-51. (Pubitemid 23220677)
20. Beall HD, Winski SL. Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development. Front Biosci 2000;5:D639.
21. Breider MA, Pilcher GD, Graziano MJ, Gough AW. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol 1998;26:234-9. (Pubitemid 28155329)
22. Siim BG, Menke DR, Dorie MJ, Brown JM. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 1997;57:2922-8. (Pubitemid 27315040)
23. Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005;23:9097-104.
24. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007;13:3922-32. (Pubitemid 47037600)
25. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, et al. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 2010;65: 791-801.
26. Williams KJ, Albertella MR, Fitzpatrick B, Loadman PM, Shnyder SD, Chinje EC, et al. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. Mol Cancer Ther 2009;8:3266-75.
27. Papadopoulos KP, Goel S, Beeram M, Wong A, Desai K, Haigentz M, et al. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res 2008;14:7110-5.
28. Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 2011 Dec 6. [Epub ahead of print].
29. Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008;51:2412-20. (Pubitemid 351628502)
30. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010;116:1524-7.
31. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, et al. Phase 1 study of the safety, tolerability and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 2011;17:2997-3004.
32. Hureaux J, Lagarce F, Gagnadoux F, Rousselet MC, Moal V, Urban T, et al. Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice. Pharm Res 2010;27:421-30.
33. Ljungkvist AS, Bussink J, Kaanders JH, Wiedenmann NE, Vlasman R, van der Kogel AJ. Dynamics of hypoxia, proliferation and apoptosis after irradiation in a murine tumor model. Radiat Res 2006;165:326-36.
34. Boyd MR, Kenneth DP. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Development Res 1995;34:91-109.
35. Dykes DJ, Abbott BJ, Mayo JG, Harrison SD Jr, Laster WR Jr, Simpson-Herren L, et al.Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. In: Fiebig HH, Berger DP, editors. Immunodeficient Mice in Oncology. Base: Karger; 1992. p. 1-22.
36. Chen Y, Cui T, Knösel T, Yang L, Zöller K, Petersen I. IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation. Lung Cancer 2011;73:38-44.
37. Rajesh D. Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. Mol Pharm 1999;56:515.
38. Lin X, Howell SB. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Therap 2006;5:1239-47. (Pubitemid 43881316)
39. Czerwinski M, McLemore TL, Gelboin HV, Gonzalez FJ. Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res 1994;54:1085-91. (Pubitemid 24085467)
40. Raleigh JA, Chou SC, Arteel GE, Horsman MR. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 1999;151:580-9. (Pubitemid 29381608)
41. Matsumoto K, Szajek L, KrishnaMC, Cook JA, Seidel J, Grimes K, et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Oncol 2007;30:873-81.
42. Shin KH, Diaz-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF, et al. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther 2007;6:70-5. (Pubitemid 46294179)
43. Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, et al.DNAcross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. Cancer Res 2009;69:3884-91.
44. Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother Oncol 2006;78:138-45. (Pubitemid 43344172)
45. Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI. Exploring vascular dysfunction caused by tirapazamine. Microvasc Res 2008; 75:247-55. (Pubitemid 351240940)
46. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: the histone guardian of the genome. DNA Repair (Amst.) 2004; 3:959-67. (Pubitemid 38997938)
47. Hammond EM, Dorie MJ, Giaccia AJ. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Bio Chem 2003;278;12207-13. (Pubitemid 36800201)
48. Olive PL, Banáth JP, Sinnott LT. Phosphorylated histone H2AX in spheroids, tumors, and tissues of mice exposed to etoposide and 3-amino-1,2,4-benzotriazine-1,3-dioxide. Cancer Res 2004;64: 5363-9. (Pubitemid 39006557)